Nanoform Wins Award for Drug Development and Delivery – AZoNano

Image Credit: phive/Shutterstock.com

Nanoform, a Finnish nanotechnology and drug particle engineering company, has won the prestigious Excellence in Pharma Award for Formulation at the 16th CPhI Pharma Awards which took place in Germany this November.

The prize sees world-renowned innovative companies competing against one another. This year Nanoforms ingenious medicine enabling nanotechnology, in the form of its CESS nanonization technology, won the highly contested award.

Who are Nanoform?

International pharmaceutical and biotechnology companies are well aware of the work that Nanoform dedicates itself to. Nanoform partners with businesses with the aim to boost their molecules formulation performance as well as to reduce clinical attrition. Nanoform is committed to working with international companies to provide them with cutting-edge, innovative solutions for the development and delivery of drugs.

The technology that won it the esteemed prize at the CPhI Pharma Awards was its multi-patented nanonization process which was designed with the capability of substantially improving dissolution rates and bioavailability, having the impact of doubling the number of drug compounds reaching clinical trials. In addition, the innovation has been shown to add value to the drug delivery spaces of pulmonary, transdermal, ocular and blood-brain barrier.

For this innovative new process, Nanoform surpassed the efforts of other respected companies such as Cambrex, Lonza Capsugel, and Glatt Pharmaceutical Services, who had also entered in the same category.

The Innovation

The new CESS, short for Controlled Expansion of Supercritical Solutions, nanonization technology has multiple patents for its unique design. It creates designed-for-purpose, nano-sized active pharmaceutical ingredient (API) particles, using a process that can control the particles shape, increasing uniformity. The system also has the ability to produce nanoparticles as small as 10 nm.

The method works by controlling the solubility of an API in supercritical carbon dioxide (scCO2) through a bottom-up method of recrystallization. Previous alternatives had been limited, and the CESS system surpasses those due to its utilization of controlled mass transfer, pressure reduction and flow. Another benefit of the system is that it is green, its process is free from using excipients and organic solvents.

Through Nanoforms innovation, novel opportunities are opening up to the field of drug research and development.

The Significance of the CESS System

Nanomaterials have unique properties that differ from their bulk material counterparts. These different properties have made them of special interest to a number of scientific fields, which has boosted exploration into nanoparticles over recent years. It has been found that these unique properties have potential applications in the areas of nanomedicine, therapeutics, medical devices and more. They have been identified as vectors for medical imaging, biological diagnostics and therapeutics.

What has been achieved by Nanoform is that another avenue of potential use has been opened up for nanoparticles. Nanoform has developed a reliable system that allows the benefits of nanoparticles to be harnessed in drug research and development. The unique properties of nanoparticles will be able to be put to use in developing new therapeutic treatments, which could induce a significant shift in the pharmaceutical sector.

It is generally accepted that advancements in the use of nanoparticles in this area would significantly influence the advancement of human therapeutics. Now pharmaceutical companies have access to a system that allows them to tailor-make nanoparticles, the innovation of new therapies that previously would not have been possible could be on the horizon.

Read the original post:
Nanoform Wins Award for Drug Development and Delivery - AZoNano

If You Had Bought Avecho Biotechnology (ASX:AVE) Stock Five Years Ago, You’d Be Sitting On A 94% Loss, Today – Yahoo Finance

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. For example, we sympathize with anyone who was caught holding Avecho Biotechnology Limited (ASX:AVE) during the five years that saw its share price drop a whopping 94%. On top of that, the share price has dropped a further 33% in a month.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

See our latest analysis for Avecho Biotechnology

We don't think that Avecho Biotechnology's modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. It would be hard to believe in a more profitable future without growing revenues.

Over five years, Avecho Biotechnology grew its revenue at 6.2% per year. That's a fairly respectable growth rate. So the stock price fall of 44% per year seems pretty steep. The truth is that the growth might be below expectations, and investors are probably worried about the continual losses.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

ASX:AVE Income Statement, November 12th 2019

Take a more thorough look at Avecho Biotechnology's financial health with this free report on its balance sheet.

We're pleased to report that Avecho Biotechnology shareholders have received a total shareholder return of 33% over one year. That certainly beats the loss of about 43% per year over the last half decade. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

Here is the original post:
If You Had Bought Avecho Biotechnology (ASX:AVE) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today - Yahoo Finance

Where Does ISEE Stock Rank in the Biotechnology Industry? – InvestorsObserver

IVERIC bio Inc (ISEE) is near the top in its industry group according to InvestorsObserver. ISEE gets an overall rating of 62. That means it scores higher than 62 percent of stocks. IVERIC bio Inc gets a 87 rank in the Biotechnology industry. Biotechnology is number 99 out of 148 industries.

Click Here to get the full Stock Score Report on IVERIC bio Inc (ISEE) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

IVERIC bio Inc (ISEE) stock is lower by -7.35% while the S&P 500 is up 0.32% as of 1:06 PM on Tuesday, Nov 12. ISEE is lower by -$0.25 from the previous closing price of $3.40 on volume of 899,010 shares. Over the past year the S&P 500 is up 13.60% while ISEE is up 45.83%. ISEE earned $1.70 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 1.85.

To see InvestorsObservers Sentiment Score for IVERIC bio Inc click here.

Read more:
Where Does ISEE Stock Rank in the Biotechnology Industry? - InvestorsObserver

Opinion | The fast-evolving ethical conundrums of biotechnology – Livemint

In the information technology world, we have seen an explosion of Artificial Intelligence, automation, blockchains and data science tools in the last few years. All of these technologies, while distinct in their approach, actually cross-pollinate each other. The worlds denizensand their governmentshave rightly started to worry about issues such as data privacy, control over fiat currencies, job losses and widening income disparities. I had written in this column earlier that governments started getting significantly more active in the regulation of this space in 2018.

Sure enough, this debate has continued into 2019. These questions are not simply for governments and philosophers; the world needs leadership and self-governance by technology giants in the formation of ethics to help us navigate turbulent times ahead. In my opinion, most attempts at self-governance came after the negative effects of new technologies were felt. The profit motive did not allow for Big Tech to pause before it rushed headlong into grey areas. Now that the world has begun to call them out, they claim to be in ethical introspection mode.

There is another area of technology that is beginning to raise concerns. Technology and bioengineering have begun to take over in the life sciences industry. We have already seen ethical questions that arose from a Chinese experiment on interfering with the DNA of babies. Our capacity to re-engineer the biological world is truly mind-boggling in its scope now, and many technological offshoots attempt to fuse man and machine into a cohesive super-human".

I was recently in Cambridge, Massachusetts, visiting my sister Seeta Pai and brother-in-law James Gray, who both hold doctoral degrees from Harvard in human development. Cambridge has become a hotbed for bio-tech innovation and startups. Gray works for MIT Media Lab and gave me a quick tour.

Thankfully, the MIT Media Lab, along with other bodies, has established a Community Biotechnology Initiative to both share tools and research as well as create an ethical framework for the worlds researchers to follow. This is to be done by engendering discussions by researchers and hosting various events to facilitate such debates.

One such event is the Global Community Bio Summit. During its recent 2019 conference, it came out with a list of ethical principles that bio-tech researchers will have to ask themselves on a regular basis. The fact that these questions have already been identified before the damage is done is an important achievement that sharply contrasts with the approach of Big Tech.

In the rest of this column, I will paraphrase the Bio Summits list of areas where ethical conundrums lie, while attempting to remain faithful to the original text with some of the questions suggested for further reflection. This list is enough to engender thought along several vectors. The summit said that these could be applied in any community bio" context, but made clear that it was not a central fiat. It is just a list that would allow for discussions in both local and global contexts.

One, respect: How can we prioritize the rights of humans, animals and ecosystems? How can we attune our ways so that our practices do not harm other living beings?

Two, credit: How do we make sure our work serves as a resource for the community and the broader public while still valuing those who do the work?

Three, community: How do we make decisions collectively? How do we identify and engage non-bio stakeholders?

Four, autonomy: How do we decide what forms of self-determination we value? How do we identify relationships of power that impact autonomy?

Five, education: How can we create space to learn and the confidence to teach?

Six, open science: How can we encourage replicability and collaboratively share results? How do we stay open while being mindful of the risks posed by openness?

Seven, transparency: How do we stay open about our failures? How can we acknowledge ethical conflicts? How do we decide what acceptable funding sources are?

Eight, data privacy: How do we respect the sovereignty of data, treat stakeholders as peers, and agree on terms of use through informed consent?

Nine, safety: How do we embrace safe practices in unconventional contexts? How do we protect each other and create resources for communities to experiment safely?

Ten, justice and fairness: How do we engender justice and fairness in our practices? How can we avoid perpetuating systems of winners and losers? How do we account for the varied impact of our work?

Eleven, diversity and inclusion: How do we make sure our organizations respect vulnerabilities and acknowledge privilege? How do we make our spaces valuable and accessible to communities whose interests are historically under-represented in the sciences?

And twelve, accountability: Is there an active commitment to consider these questions? How will we be accountable to these ethics? How do we hold each other accountable and make ourselves accountable to those outside this community?

It is heartening to note that the scientific community, unlike its technology counterpart, is beginning to consider these questions at the outset, long before we find ourselves overrun by droids and Frankensteins

Siddharth Pai is founder of Siana Capital, a venture fund management company focused on tech

Read more here:
Opinion | The fast-evolving ethical conundrums of biotechnology - Livemint

Where Does CLVS Stock Rank in the Biotechnology Industry? – InvestorsObserver

Clovis Oncology Inc (CLVS) is near the top in its industry group according to InvestorsObserver. CLVS gets an overall rating of 50. That means it scores higher than 50 percent of stocks. Clovis Oncology Inc gets a 67 rank in the Biotechnology industry. Biotechnology is number 99 out of 148 industries.

Click Here to get the full Stock Score Report on Clovis Oncology Inc (CLVS) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 50 means the stock is more attractive than 50 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Clovis Oncology Inc (CLVS) stock is trading at $5.51 as of 1:00 PM on Tuesday, Nov 12, an increase of $0.13, or 2.32% from the previous closing price of $5.38. The stock has traded between $5.25 and $5.91 so far today. Volume today is 4,592,272 compared to average volume of 5,433,499.

To screen for more stocks like CLVS click here.

Here is the original post:
Where Does CLVS Stock Rank in the Biotechnology Industry? - InvestorsObserver

Biotechnology Reagents Market Analysis, International Marketing, Research Report With Top Industry Players – Galus Australis

Biotechnology Reagents Market is an expert and inside-out market report that spotlights on market share, potential deals volume, driving portions and geological investigation of Biotechnology industry. It additionally contains the drivers and limits for the market that are gotten from SOWT examination, and furthermore demonstrates what all are the ongoing Biotechnology Reagents Market advancements, product launches, joint endeavors by the few key players and brands that are driving the market are by foundational organization profiles. It demonstrates that the ascent in market is for the most part credited to the rising development of the relevant enterprises and the resulting ascends popular of uses.

For More Details Get A Sample Copy Of This Biotechnology Reagents Market Report: https://databridgemarketresearch.com/request-a-sample/?dbmr=global-biotechnology-reagents-market

Introduction

This Biotechnology Reagents report introduce definition, classification, specification and application, market overview, market dynamics, market segmentation, raw materials, Industry policies, etc.

Analysis of the market

This Biotechnology Reagents report utilizes different types of the analysis of the market like SWOT analysis, Ports Five analysis which examines weakness, threats, drivers and restraints of the market.

Regional analysis of the market

This Biotechnology Reagents report focuses on key regions such as North America, South America, Asia and Pacific region, Middle east and Africa and Europe

Segmentation of the market

This Biotechnology Reagents report has been divided into type, application, geographical landscape with production Consumption, revenue, market share and growth rate of the Biotechnology Reagents market.

Sub Segments:

By Geography

North America (U.S., Canada, Mexico)

South America (Brazil, Argentina, Rest of South America)

Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe)

Asia-Pacific ( Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific)

Middle East & Africa (South Africa, Egypt, Saudi Arabia, United Arab Emirates, Israel, Rest of Middle East & Africa)

To Get An Idea About The Biotechnology Reagents Report, Avail The TOC Here: https://databridgemarketresearch.com/toc/?dbmr=global-biotechnology-reagents-market

Key Market Competitors:

Few of the major competitors currently working in the biotechnology reagents market are Abbott, Agilent Technologies Inc., Danaher, BD, Bio-Rad Laboratories Inc., General Electric, bioMrieux SA, LONZA, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Hoefer, Inc., Meridian Bioscience, Inc., PerkinElmer Inc., Merck KGaA, Promega Corporation, Quality Biological, Siemens AG, Bio-Techne, TAKARA HOLDINGS INC., Sysmex Corporation, Tosoh Corporation, WATERS, W. R. Grace & Co.-Conn., Ortho Clinical Diagnostics, Olympus Corporation and Fitzgerald Industries International among others.

What are the demands provided in the market?

This Biotechnology Reagents report focuses on the demands of the clients that helps to establish their business successfully. It also provides the guidance to overcome the upcoming obstacles by providing the unbiased picture of the market in the precise manner.

Which factors does this Biotechnology Reagents report includes?

This Biotechnology Reagents report includes a historic data and analysis of the key industry, six year forecast of the market and emerging trends, An assessment of the competitive landscape and market shares for major companies and much more

Conclusion:

The data included in this Biotechnology Reagents report is reliable, thoroughly researched and verified by the research analyst. It keeps you a step ahead by providing up dated information regarding the Industry which will help you to make faster and better decisions.

Want Full Report? Make Inquiries For Your Custom Requirements: https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-biotechnology-reagents-market

About Us

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing Corporatesales@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.comhttps://databridgemarketresearch.com

Read the original here:
Biotechnology Reagents Market Analysis, International Marketing, Research Report With Top Industry Players - Galus Australis

Global Marine Biotechnology Markets Report 2019: Market is Expected to Grow from USD 3.5 Billion in 2017 to USD 6.5 Billion in 2024 – Yahoo Finance

DUBLIN, Nov. 11, 2019 /PRNewswire/ -- The "Global Marine Biotechnology Market" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global marine biotechnology market is expected to grow significantly from USD 3,500.4 million in 2017 to USD 6,500.6 million in 2024, at a CAGR of 9.61% from 2018 to 2024.

The growth in the market is attributed to the rising usage of marine biotechnology in various industries, advances in drug discovery and growing expenditure in R&D activities. Moreover, increasing demand for eco-friendly products is further propelling the market growth.

Key findings from the report:

The years used for the assessment are as follows;

Key Topics Covered:

CHAPTER 1. Market Scope and Methodology1.1. Research methodology1.2. Research scope & assumptions1.3. List of data sources

CHAPTER 2. Executive Summary2.1. Marine Biotechnology- Market Snapshot

CHAPTER 3. Industry Analysis3.1. Market definition3.2. Market segmentation3.3. Key findings of the global marine biotechnology market3.4. Value chain analysis3.4.1. By end-use Industries3.5. Market opportunities & trends3.5.1. Increasing usage of marine biotechnology for the development of biofuels3.5.2. Rising investment and collaborations in translational research3.6. Market driver analysis3.6.1. Rising usage of marine biotechnology in various industries3.6.2. Advances in drug discovery3.6.3. Increasing demand for eco-friendly products3.7. Market restraint analysis3.7.1. Fluctuations in prices of crude oil3.7.2. Difficulty in sampling the huge diversity of resources

CHAPTER 4. Competitive Outlook4.1. Competitive analysis4.1.1. Industry Analysis-Porters five forces analysis4.1.2. Company Share Analysis4.2. Competitive factors

CHAPTER 5. Global Marine Biotechnology Market Size and Forecast (2014 - 2024)5.1. Global Marine Biotechnology Market, By Source5.1.1. Algae5.1.2. Annelids5.1.3. Bacteria5.1.4. Bryozoa5.1.5. Cnidaria5.1.6. Crustacea5.1.7. Fungi5.1.8. Echinoderms5.1.9. Fishes5.1.10. Molluscs5.1.11. Nemertinea5.1.12. Protozoa5.2. Global Marine Biotechnology Market, By Product5.2.1. Bio Active Substances5.2.2. Bio Material5.2.3. Others5.3. Global Marine Biotechnology Market, By Technology5.3.1. Isolation and Cultivation of Microorganisms5.3.2. Culture-Independent Techniques5.4. Global Marine Biotechnology Market, By Application5.4.1. Aquaculture and Food Products5.4.2. Environmental and Human Health5.4.3. Drug Discovery5.4.4. Pollution Remediation5.4.5. Wastewater & Waste Disposal5.4.6. Biofuels5.4.7. Others5.5. Global Marine Biotechnology Market, By End-user5.5.1. Food Industry5.5.2. Pharmaceutical and Biotech5.5.3. Cosmetics5.5.4. Chemical5.5.5. Energy5.5.6. Others

CHAPTER 6. Global Marine Biotechnology Market, By Geography6.1. North America Marine Biotechnology Market6.1.1. North America Marine Biotechnology Market, By Source (USD Million)6.1.2. North America Marine Biotechnology Market, By Product (USD Million)6.1.3. North America Marine Biotechnology Market, By Technology (USD Million)6.1.4. North America Marine Biotechnology Market, By Application (USD Million)6.1.5. North America Marine Biotechnology Market, By End-user (USD Million)6.1.6. North America Marine Biotechnology Market, By Country6.1.6.1. U.S.6.1.6.2. Canada6.1.6.3. Mexico6.2. Europe Marine Biotechnology Market6.3. Asia-Pacific Marine Biotechnology Market6.4. Centeral and South America Marine Biotechnology Market6.5. Middle East and Africa Marine Biotechnology Market

CHAPTER 7. Key Players and Strategic Developments7.1. Business Overview7.2. Product and Service Offering7.3. Financial Overview7.4. Strategic Developments

Story continues

Link:
Global Marine Biotechnology Markets Report 2019: Market is Expected to Grow from USD 3.5 Billion in 2017 to USD 6.5 Billion in 2024 - Yahoo Finance

Goodwin Biotechnology Launches a Digitization Initiative by Investing in a Sophisticated Electronic Quality Solution – PRNewswire

FORT LAUDERDALE, Fla., Nov. 6, 2019 /PRNewswire/ --Goodwin Biotechnology, Inc. announced that it has recently licensed an industry leading electronic content and document management solution to enhance the efficiency and effectiveness of its Quality systems and operations. This improvement continues to ensure that Goodwin Biotechnology remains uniquely positioned as aqualified and flexible biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that offers an integrated Single Source Solution from Cell Line Development, Process Development and cGMP manufacturing including Scale-Up, cGMP Contract Manufacturing, and Aseptic Fill / Finish of mammalian cell-culture derived monoclonal antibodies, recombinant proteins, vaccines, and Antibody Drug Conjugates (ADCs).

"Acquisition and implementation of this sophisticated electronic solution demonstrates Goodwin's commitment to providing top-tier development and manufacturing services for our clients," noted Karl Pinto, Chief Executive Officer at Goodwin Biotechnology. "Goodwin's past successes supporting our clients through their early- and late-stage clinical trials, and regulatory compliant commercial manufacturing, will be strengthened through this recent investment. These strategic steps demonstrate our commitment to effectively support our clients through all stages of product development and cGMP manufacturing to assure conformance to worldwide regulatory standards." added Mr. Pinto.

About Goodwin Biotechnology, Inc.Goodwin Biotechnologyis a uniquely qualified and flexible, US-based CDMO that offers a Single Source Solution to enhance the value of complex biopharmaceuticals for our clients. With over 26 years of experience as an independent integrated contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Based on the impressive track record, Goodwin Biotechnology has received numerous industry awards that span from Frost & Sullivan's Customer Value and Leadership Award for Best Practices in Mammalian Contract Manufacturing to the Biologics cGMP Manufacturer of the Year 2018 by Global Health & Pharma News. Click here to view the press releases! Additional information may be found at http://www.GoodwinBio.com.

For more information, please contact:

SOURCE Goodwin Biotechnology, Inc.

http://www.goodwinbio.com

Visit link:
Goodwin Biotechnology Launches a Digitization Initiative by Investing in a Sophisticated Electronic Quality Solution - PRNewswire

VBI Vaccines Inc. (VBIV) vs. TIM Participacoes S.A. (TSU): Comparing the Biotechnology Industrys Most Active Stocks – E Globalist

VBI Vaccines Inc. (NASDAQ:VBIV) shares are down more than -65.31% this year and recently increased 0.84% or $0.01 to settle at $0.56. TIM Participacoes S.A. (NYSE:TSU), on the other hand, is up 4.29% year to date as of 11/08/2019. It currently trades at $15.38 and has returned 7.70% during the past week.

VBI Vaccines Inc. (NASDAQ:VBIV) and TIM Participacoes S.A. (NYSE:TSU) are the two most active stocks in the Biotechnology industry based on todays trading volumes. We will compare the two companies based on the strength of various metrics, including growth, profitability, risk, return, and valuation to determine if one is a better investment than the other.

One of the key things investors look for in a company is the ability to grow earnings at a high compound rate over time. Comparatively, TSU is expected to grow at a 5.90% annual rate. All else equal, TSUs higher growth rate would imply a greater potential for capital appreciation.

Growth isnt very attractive to investors if companies are sacrificing profitability and shareholder returns to achieve that growth. We will use EBITDA margin and Return on Investment (ROI), which control for differences in capital structure between the two companies, to measure profitability and return. EBITDA margin of 11.13% for TIM Participacoes S.A. (TSU).

Cash is king when it comes to investing. VBIVs free cash flow (FCF) per share for the trailing twelve months was -0.14. Comparatively, TSUs free cash flow per share was +0.46. On a percent-of-sales basis, VBIVs free cash flow was -0.74% while TSU converted 4.79% of its revenues into cash flow. This means that, for a given level of sales, TSU is able to generate more free cash flow for investors.

VBIV trades at a P/B of 0.71, and a P/S of 25.09, compared to a forward P/E of 17.58, a P/B of 1.40, and a P/S of 1.76 for TSU. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.

Analyst Price Targets and Opinions

When investing its crucial to distinguish between price and value. As Warren Buffet said, price is what you pay, value is what you get. VBIV is currently priced at a -93.21% to its one-year price target of 8.25. Comparatively, TSU is -13.89% relative to its price target of 17.86. This suggests that VBIV is the better investment over the next year.

Insider Activity and Investor Sentiment

Comparing the number of shares sold short to the float is a method analysts often use to get a reading on investor sentiment. VBIV has a short ratio of 2.09 compared to a short interest of 4.29 for TSU. This implies that the market is currently less bearish on the outlook for VBIV.

TIM Participacoes S.A. (NYSE:TSU) beats VBI Vaccines Inc. (NASDAQ:VBIV) on a total of 7 of the 14 factors compared between the two stocks. TSU has lower financial risk, is more profitable, generates a higher return on investment, has higher cash flow per share, has a higher cash conversion rate and higher liquidity.

See the original post:
VBI Vaccines Inc. (VBIV) vs. TIM Participacoes S.A. (TSU): Comparing the Biotechnology Industrys Most Active Stocks - E Globalist

Rejoice, O Wood and Tree of Life, the Fount of Immortality – Patheos

Rejoice, O wood and tree of life, the fount of immortality. In light of recent controversy over the Amazon Synod, this particular verse from the Agni Parthene stood out as I listened to it tonight. Today is Remembrance Day in Canada, when we remember the service and sacrifice of our fallen veterans. I was taking a moment to reflect upon Heaven and the eternal peace that can only be achieved by Our Lord Jesus Christ through the intercession of His (Our!) Blessed Mother.

The title Agni Parthene is commonly translated into English as O Virgin Pure. Many Byzantine Christiansmyself includedconsider it one of the most beautiful hymns ever composed to the Blessed Mother of God.

It is certainly one of the most popular.

The hymn was composed by Greek Orthodox bishop, mystic, and miracle worker St Nectarios of Aegina sometime in the late 19th Century. Reportedly after the Blessed Mother surrounded by heavenly angels appeared to him at a monastery during a period of intense fasting and prayer. It is said that the Blessed Theotokos herself dictated the words to him, which she ask be set to the music with which this hymn became popular.

As an aside, St Nectarios is known to have consecrated deaconesses for a womens monastery that he founded, and the liturgy among Eastern Orthodox Churches by which female monastics become deaconesses is now known among Eastern Orthodox as the ritual of St Nektarios. Although the ritual itself predates the saint. His feast day is November 9, which is coming up soon in the Julian Calendar.

What struck me tonight is the reference to Our Blessed Mother as the tree of life. Within the Byzantine Christian tradition, the term tree of life usually refers to Our Lords cross. Yet here it refers to the Blessed Mother. I should not be surprised by this given that Mary, Tree of Life is a very popular and traditional icon among Eastern Orthodox and Byzantine Catholics.

I am blessed by this connection given its reminder that it is from the Blessed Theokos that Our Lord Jesus Christ received His humanity. Not just His human flesh but His whole human person. Without Mary as the Tree of Life, there would have been no hypostatic union between God and man at the Incarnation. It is through Mary, the Tree of Life, that Our Lord Jesus Christ made salvation possible.

Here are the complete lyrics, with a link to youtube recital.

******************AGNI PARTHENE

O virgin pure, Immaculate lady TheotokusRejoice, O unwedded bride

O Virgin Mother, Queen of all/ and fleece which is all dewy

More radiant than the rays of sun/ and higher than the heavensRejoice, O unwedded bride

Delight of virgin choruses/ superior to Angels.Rejoice, O unwedded bride

Much brighter than the firmament/ and purer than the suns lightRejoice, O unwedded bride

More holy than the multitude/ of all the heavnly armies.Rejoice, O unwedded bride

O Ever Virgin Mary/ of all the world, the LadyRejoice, O unwedded bride

O bride all pure, immaculate/ O Lady PanagiaRejoice, O unwedded bride

O Mary bride and Queen of all/ our cause of jubilationRejoice, O unwedded bride

Majestic maiden, Queen of all/ O our most holy MotherRejoice, O unwedded bride

More honrable than Cherubim/ beyond compare more gloriousRejoice, O unwedded bride

than immaterial Seraphim/ and greater than angelic thrones.Rejoice, O unwedded bride

Rejoice, O song of Cherubim/ Rejoice, O hymn of angelsRejoice, O unwedded bride

Rejoice, O ode of Seraphim/ the joy of the archangelsRejoice, O unwedded bride

Rejoice, O peace and happiness/ the harbor of salvationRejoice, O unwedded bride

O sacred chamber of the Word/ flowr of incorruptionRejoice, O unwedded bride

Rejoice, delightful paradise/ of blessed life eternalRejoice, O unwedded bride

Rejoice, O wood and tree of life/ the fount of immortality.Rejoice, O unwedded bride

I supplicate you, Lady/ now do I call upon youRejoice, O unwedded bride

And I beseech you, Queen of all/ I beg of you your favorRejoice, O unwedded bride

Majestic maiden, spotless one/ O Lady PanagiaRejoice, O unwedded bride

I call upon you fervently/ O sacred, hallowed templeRejoice, O unwedded bride

Assist me and deliver me/ protect me from the enemyRejoice, O unwedded bride

And make me an inheritor/ of blessed life eternal.Rejoice, O unwedded bride

Follow this link:
Rejoice, O Wood and Tree of Life, the Fount of Immortality - Patheos

Texan Spending Fortune, Hours A Day Trying To Live To At Least 120 Years Old: I Am My Asset – CBS Dallas / Fort Worth

DALLAS (CBSDFW.COM) Hundreds of pills, expensive machines and constant blood testing.

They are among the keys to immortality according the ultra-wealthy who are becoming devout followers of whats known as biohacking.

A rich Dallas and Austin developer is offering CBS 11 News a rare glimpse into the lifestyle.

Ari Rastegar (CBS 11)

Ari Rastegar goes to bed in special clothing on a temperature-regulated bed.

It has this metallic mechanism inside of it that helps flush lactic acid and eliminate inflammation, says Rastegar.

He also wears a mask.

Orange glasses that illuminate the the light so I dont disrupt the circadian rhythms, he says.

Thats just Rastegars nightly routine.

During the day, he takes nearly 150 vitamins customized to his current needs by his doctor.

Rastegar also gets his blood tested monthly.

The 37-year-old has a $15,000 vapor machine thats supposed to reduce stress and another $15,000 machine designed to calm his brain two hours before bedtime.

He says its paying off and making him healthier than ever.

I am my asset, he says.

Ari Rastegar and his vapor machine. (CBS 11)

Biohacking is all part of an effort to extend life beyond anything humans can imagine.

The data will tell you the folks that are living this type of lifestyle are living well in excess of 120 years old, says Rastegar.

The goal of biohacking is to keep strands of DNA from aging.

Rastegar has already spent hundreds of thousands of dollars.

But the real estate developer can afford it with the money he makes as CEO of Rastegar Property.

He owns buildings in Austin and is planning a $100,000,000, 26-story residential tower in the uptown section of Dallas next year.

I dont know if Im trying to live forever. Im trying to live as long as I can contribute, he says.

Rastegars exhausting daily routine also includes a hyperbaric chamber, meditation and he employs a life coach.

Rastegar is one of a growing number of longevity devotees who also undergo hormone therapy.

Others, not Rastegar, have even resorted to blood transfusions and stem cell treatments stay young.

My biological age is now that of about a 4-year-old, he says.

But medical doctors say not so fast when it comes to treatments that promise to slow down aging.

We dont have any long-term evidence-based studies to correlate whatever biohacking techniques people are using to prolong or extend life, yet, says Dr. James Pinckney of Diamond Physicians.

While physicians are cautious, Rastegar says hes seen the proof by lowering his cholesterol and raising his testosterone.

Rastegar along with a number of other millionaires and billionaires are spending vast amounts of their fortunes in the search for immortality.

But he says that doesnt mean he fears death.

I think were all little bit apprehensive, he says. I like to focus more on living, even with all this biohacking and all this stuff you dont know if youre going to make it to the next day.!

Read the original here:
Texan Spending Fortune, Hours A Day Trying To Live To At Least 120 Years Old: I Am My Asset - CBS Dallas / Fort Worth

The Suga Show Is Set To Compete At Quintet Ultra – The Official Website of the Ultimate Fighting Championship

A lot of the high-level grappling matches with straight jiu-jitsu guys, you see a lot of 50/50s and a lot of stalling in positions, OMalley said. All these guys are fighters or former fighters; these guys arent into that. The list of people I saw in this looked like a ton of killers.

With black belt after black belt in the lineup, OMalley knows he comes in as an underdog, and while hes eager to enjoy his time in his first grappling event, theres a certain pressure coming in, a pressure that helps his agenda of proving hes one of the baddest all-around fighters in the world.

Lack of experience, only a BJJ purple belt and a reputation for striking are all factors working against OMalley, but would the young man who won Fight of the Night at UFC 222 let any perceived disadvantage ruin his experience?

With the people Ive seen, the only guy thats similar size to me is Chad Mendes. I dont see anybody even close to my size, OMalley said. I feel like Im going to be a huge underdog since all of these guys are high-level black belts, but I think theres still a fun aspect to it where since its jiu-jitsu you cant really put yourself in that much of a dangerous position but anything can happen.

Read more here:
The Suga Show Is Set To Compete At Quintet Ultra - The Official Website of the Ultimate Fighting Championship

NASA Reports 2,034-Foot ‘Potentially Hazardous Asteroid’ Will Fly By Earth Before Thanksgiving – Outer Places

I never tire of thinking about how humanity will eventually go the way of the dinosaur. I find a strange kind of comfort in considering the fact that despite all of its collective vanity, aspirations towards immortality, and denial of death, humans, as a species, will eventually return to the dust whence they came. It puts life's petty hassles, indignities, and agonies into a perspective that transcends "this too shall pass" and other platitudes. Once extinct, there will be no history. There will eventually be no trace of us. If we are alone in the universe though we should remember that no evidence of extraterrestrial life does not mean there is evidence of no extraterrestrial life our planet will simply become an unmarked grave, incapable of even being forgotten because there won't be anyone left to forget.

You might want to mention that to your family and friends this Thanksgiving, because we'll be getting a little reminder of our fragility in the form of a 2,034-foot asteroid named 481394 (2006 SF6) by NASA'sCenter for Near-Earth Object Studies (CNEOS).481394 (2006 SF6) has been dubbed "potentially hazardous" by the agency due to its orbital proximity toEarth on November 20th, when it will come perilously close 2.7 million miles, according to the International Business Times to our lovely, blue-green planet that, up to this point in human history, seems to have been exceptionally lucky in not being obliterated by a flying space rock.

For context, the 56-foot Chelyabinsk meteor which exploded over Russia in 2013 struck Earth with the force of 30 atomic bombs. If481394 (2006 SF6) were to be steered by an exceptionally bellicose extraterrestrial force or whatever into Earth, the results would be devastating, though they would negate the necessity of tolerating your vaguely-racist Aunt Sharon and sneaking off to chug vodka purloined from your parents liquor cabinet the following week. In any case, it's something to think about the next time you're admiring the stars or wondering how many miles you'll have to run to burn off that second helping of green bean casserole.

Fortunately, this one won't hit us. Unfortunately,NASA has a history ofnotnoticing incoming asteroidsand has already admitted it may be unable to stop an apocalypse-by-asteroid, so count your blessings on Thanksgiving.

Originally posted here:
NASA Reports 2,034-Foot 'Potentially Hazardous Asteroid' Will Fly By Earth Before Thanksgiving - Outer Places

The 10 Best TV Versions of Dracula, Ranked | ScreenRant – Screen Rant

Bram Stokers literary legend Dracula is the most frequently adapted fictional character of all time. His 1897 novel, which has now been translated into 29 languages, inspired a staggering 272 iterations of the Prince of Darkness in film and television. Some are faithful adaptations of the story, about solicitor Jonathan Harker and his dealings with the Count between Transylvania and London, while others choose to take a different approach by putting Dracula in a modern setting.

RELATED: 10 Universal Classic Monster Movies, Ranked

The character has been used as a prestigious guest star, or as a powerful adversary to elevate episodes of everything from The Brady BunchtoBuffy the Vampire Slayer. When given his own series, both the tragedy and the allure of his immortality has been explored, as well as the origins of his curse. Hes been portrayed as either the ultimate villain or a sympathetic victim of circumstance, a charismatic and cultured aristocrat or an animistic and aggressive hedonist. To prepare for BBC's three-part adaption of Draculadue on Netflix Dec. 20th, 2019 here arethe 10 best TV versions of Dracula, ranked.

Despite being the most powerful vampire of literary legend, Dracula isnt all that impressive in Buffy the Vampire Slayer when he suddenly arrives in Sunnydale. He can transform into a bat or turn into mist, but these are abilities discredited as nothing more than parlor tricks by Spike and the rest of the Scoobies. He attempts to hypnotize Buffy several times but routinely fails, making us wonder if Dracula has been de-fanged.

Hes portrayed as every bit the mysterious and seductive Prince of Darkness by Rudolf Martin, complete with pale arched cheekbones, long nails, and dark hair, but the series makes Dracula out to be just another uber vamp, not even as powerful as a Vengeance Demon. At the end of his stay in Sunnydale he has two choices; get staked or scram, and he chooses the latter.

RELATED:Buffy The Vampire Slayer: 10 Scariest Monsters, Ranked

The classic British actor Denholm Elliot, who you might remember fondly as Marcus, the trusty traveling companion of Indiana Jones in Spielbergs classic adventure trilogy, donned the cape and fangs to portray Dracula in a television serial called Mystery and Imagination in 1968. His version was very operatic and melodramatic, calling to mind Bela Lugosis original film version in the 30s.

Denholm Elliot is an accomplished thespian, but perhaps hes simply too likable and too congenial to accurately pull off the Count. While we could believe that anyone would accept an invitation from his Dracula to have a nice dinner, we couldnt believe that he would make anyone into a nice dinner. He was all bat and no bite.

In 2006, because there hadnt been a Dracula film in a few years, the BBC decided it was about time to have a go at Bram Stokers famous vampire story. The master of producing period films, BBC was always going to create a sumptuous story around the Count, but where would it differ from the version directed by Francis Ford Coppola in the 90s with Gary Oldman and Winona Ryder?

Marc Warrens Dracula is young, brash, and arrogant. Hes a caged beast waiting to break free, which has more in common with the Wolfman than Dracula (who has in the past weaponized the Wolfmans uncontrollable impulses for his own uses). This Dracula isnt terrifying nor is he charismatic - he simply exists for the purpose of pouting for the post-Twilight crowd.

RELATED:BBC's Dracula: Everything We Know About The Series From The New Trailer

The atmospheric fantasy series Penny Dreadful,about a group ofuniquely skilled individuals hunting supernatural creatures in Victorian London, featured several famous horror legends of literature. Dr. Frankenstein and his Monster, Dorian Grey, the Wolfman, and of course, Dracula himself.

Posing as Dr. Sweet, he befriended Ms. Vanessa Ives, a clairvoyant in Sir Malcolms employ. They bonded over their mutual love of ancient artifacts, literature, and poetry. With such an intellectual fascination, it was only a matter of time before a physical one manifested, but his identity was discovered before he could make her into a meal.

While this version of Bram Stokers Dracula doesnt tread any new ground, it does include a scenery-chewing performance by Jack Palance, whom most will know from his various roles in Westerns as a tough-as-nails outlaw heavy. Its easy to believe he can overpower Jonathan Harker in this film and seduce his fiance Mina once he travels to London.

Palances Dracula is a brooding and aggressive hunter, and his bold physicality makes it feel like hed just as soon brawl you as he would bite you. It was directed by Dark Shadows creator Dan Curtis, and is atmospheric, violent, and bloody, as any good Dracula film should be.

Shortly after he appeared in Buffy the Vampire Slayer, Rudolf Martingot another chance to playDracula in a made-for-tv movie about Vlad the Impaler, the historic figure that inspired Bram Stokers novel. It traces his origins at the start of the Turkish conflict against the Ottoman Empire, and what the Count sacrificed to protect his people.

This sympathetic portrayal of the Count, which has more in common with the origins film Dracula: Untold starring Luke Evans, is a gripping story that is well-acted for its medium and offers a unique insight into the ethnic culture that Dracula came from. Its easy to see how the myths of vampires were born in the folklore of the region from this brutal and engaging tale.

Though billed as a comedic series, the fun of Dracula in Young Dracula comes from the Prince of Darkness taking himself entirely too seriously. Hes fled Transylvania with his family and moved to a small English town, where his children must enroll in the local school and try their best to blend in, despite living in a spooky castle and having a dad that looks something between a vampire and a rock star.

His son Vlad tries to juggle homework and dating with his studies of the dark arts. As Draculas son and heir, its his duty to unite all the vampire clans. Unfortunately, Vlad hates blood, killing, and anything to do with his heritage. The Count spends the series wreaking havoc on the townspeople, spouting hilarious catchphrases, and trying to thwart his sons every effort to be more like pathetic breathers.

It was like a stake to the heart of viewers when NBC canceled Dracula after only one season. The period series took a different path from Bram Stokers novel, and instead of Dracula arriving in London in 1897, he arrived in New York City at the dawn of the new century. He lets a grand house and poses as American entrepreneur Alexander Grayson, studying advancements in technology by day and hunting for victims by night.

Jonathan Rhys-Meyers Dracula has more in common with Thomas Edison and Nikola Tesla, presenting intriguing questions about modern science in Victorian society. He also has his own personal bodyguard Renfield, who is much more like Batmans manservant Alfred than he is like the cockroach-eating minion of past incarnations.

Considered one of the most faithful adaptations of Bram Stokers novel, Count Dracula was a three-part mini-series that aired on the BBC in 1977 and starred Louis Jourdan as the titular antagonist. The Count once again leaves his castle in Transylvania after meeting with English solicitor Jonathan Harker to wreak havoc on London, and take Harkers fiance Mina as his new bride.

Jourdan is credited with creating one of the most enigmatic embodiments of the legendary horror icon, combining Continental etiquette with an icy coldness that is the best amalgamation of cinematic Dracula performances by Bela Legosi and Sir Christopher Lee.

In the hit anime series Castlevania, based on the popular manga and video game series of the same name, Vlad Tepes is a tragic figure tortured by his immortality and imprisoned by his powers. He watched as the woman he loved was murdered for witchcraft, and sold his soul to the Devil in order to command the powers needed to take his revenge upon her killers.

Not only do we see Draculas origins, but we also see what became of his family lineage, as a dynasty of immortals ends up shaping the landscape of medieval Europe. The series shows Dracula at his most insanely powerful, as well as at his most vulnerable. Seasons 1 and 2 are currently streaming on Netflix.

NEXT:10 Best Versions Of Dracula, Ranked

Tags:dracula,castlevania,Penny Dreadful

Original post:
The 10 Best TV Versions of Dracula, Ranked | ScreenRant - Screen Rant

21 active stars who should have their jersey retired someday – ABS-CBN Sports

FILE - CLEVELAND, OH - MAY 05: LeBron James #23 of the Cleveland Cavaliers celebrates after hitting the game winning shot to beat the Toronto Raptors 105-103 in Game Three of the Eastern Conference Semifinals during the 2018 NBA Playoffs at Quicken Loans Arena on May 5, 2018 in Cleveland, Ohio. (Photo by Gregory Shamus/Getty Images)

By Sekou Smith, NBA.com

Tony Parker is the latest all-time great to see his jersey raised to the rafters for his years of service in San Antonio.

But he wont be the last of his generation to be honored that way. Parker big night in San Antonio generated some interesting conversation about who, among current NBA players only, would be in line for similar honors someday.

Keep in mind that the standards for a retired jersey with one franchise differs from one to another. Winning titles in Los Angeles or Boston -- or even Chicago or Golden State -- is a tougher sell than it is where there arent already multiple championship banners.

Accomplishments matter and so does sentiment, too. There are always unique variables at work when it comes to retiring jerseys, which is a much more significant honor than inducting a player into a franchises ring of honor.

With Parkers star-studded ceremony still fresh in our minds, heres a list of other stars who will one day be able to see their jerseys up in the rafters:

* * *

LeBron James (Cavs and Heat): If there is anyone thats an absolute lock to see his jersey raised high when he calls it a career, its LeBron. He delivered Cleveland a title, ending the citys 52-year title drought, in his second stint with what is essentially his hometown team. Before that, he was the catalyst for the Heats four straight Finals trips (2011-14) and back-to-back titles in 2012 and 2013. The standard to join the Lakers retired-jersey fraternity is tougher, of course. The greatest Lakers get statues -- a fate that might await LeBron in Cleveland one day.

Stephen Curry, Kevin Durant, Klay Thompson, Draymond Green and Andre Iguodala (Warriors): Also known as the Hamptons 5, they will all be immortalized someday by Golden State. All five played a role in the championship fun and excitement they generated during the franchises golden era of the past half-decade. You can make case for all five of them to enjoy jersey retirement ceremonies on their own. That, however, would go against everything their Strength In Numbers era was about. Rest assured, though, that all five of them will have their day.

James Harden (Rockets): Harden started his career as a super sixth man in Oklahoma City before rewriting his legacy after a trade to Houston. Hes already one of the most prolific and creative scorers the league has seen. The Rockets have had their fair share of legendary players and know what its like to bask in the championship glow provided by the rise of a transcendent player. Hardens jersey will be in good company some day, perhaps right next to Hakeem Olajuwons No. 34.

Russell Westbrook (Thunder): In an era where nearly every other elite superstar of his generation made a move via trade or free agency, Westbrook stuck to his roots in Oklahoma City until he had no choice but to move on. He endeared himself to generations of OKC fans by playing at a fever pitch from start to finish, earning All-Star, All-NBA and Kia MVP honors there. Being a part of a Finals team with Durant and Harden helped cement his legacy. Although hes now in Houston, hell always have a place in the hearts of Thunder fans.

Damian Lillard (Blazers): Lillard personifies the values of a basketball-mad fan base in a city that adores its team and stars in a unique way. The Blazers did their homework on the unheralded point guard from Weber State and have enjoyed everything thats happened since. From his Kia Rookie of the Year campaign in 2013 to today, he has played out better than anyone could have imagined. Lillard, one of the most underappreciated stars of his generation, couldnt have found a better match in a city and franchise.

Giannis Antetokounmpo (Bucks): The rise of the "The Greak Freak" from obscure prospect to Kia MVP in just six seasons gives his story extra dramatic flair. His relentless work ethic helped change the culture in Milwaukee and branded him as a potential successor to James as the face of the league. The fact that he authored the greatest individual season in Bucks history since Kareem-Abdul Jabbars days has carved out a permanent space for Antetokounmpos jersey in franchise lore.

Kemba Walker (Hornets): The face of the franchise in Charlotte for the first eight years of his career, Walker has since moved on to Boston. But he remains the Hornets career leader in several categories and was a beloved fan favorite for a team that never achieved any sustained postseason success. Few players of his or any era forged a connection to a city and franchise as Walker did with Charlotte.

Derrick Rose (Bulls): Born and raised in Chicago, Rose (at 22) became the youngest player to win the Kia MVP in 2011. He also joined Michael Jordan and Elton Brand as the only Bulls to win Rookie of the Year honors. Even though knee injuries derailed his career in his hometown, he piled up enough early career accolades to one day be honored with a retired jersey. Although he never led the franchise back to championship prominence, he is the the most decorated Bull since MJ.

Vince Carter (Raptors): How many players can say they served as the basketball inspiration for an entire nation? Carter can. His time with the Raptors served as the spark for generations of future NBA players, many of whom have gotten the chance to play with their childhood idol in the twilight of his future Hall of Fame career. His five seasons with the New Jersey Nets solidified his status as one of the best players of his generation. But his star was never brighter than it was from 1998-2004 when Vinsanity inspired Canada.

Marc Gasol and Mike Conley (Grizzlies): These two should grit and grind their way to the rafters in Memphis, on the same night if possible. They helped usher in the greatest run in franchise history, spearheading a feisty and physical style that spoke to the citys blue-collar ways. The Grit and Grind Grizzlies validated their rise to prominence with a West finals run in 2013 steered by Gasol and Conley.

Kyle Lowry and DeMar DeRozan (Raptors): Lowry and his best buddy DeRozan were separated before they could realize their dreams of winning a title together in Toronto. Lowry realized it last season alongside Kawhi Leonard, thus cementing his legacy as an all-time great Raptor. Hell always have a place to call home north of the border because of the franchise-altering success that took place on his watch. DeRozan was a fan favorite who wanted to finish his career in Toronto. He, too, will always have a home in the city.

Blake Griffin and Chris Paul (Clippers): The LA end for these two was messier than it should have been, especially since they oversaw the Lob City era that revitalized the franchise. Time will surely heal all wounds, somewhere down the road. History will be kinder to the Clippers climb out of the doldrums than anyone was during their injury-tortured run. Griffin and Paul are locks for the Hall of Fame one day. Plus, a franchise without much history to celebrate could use a couple of jerseys to jazz up their new building.

Kawhi Leonard (Raptors): Is a one-year surreal playoff run enough to warrant franchise immortality? Clippers fans are hoping Kawhi and Paul George give them a reason to raise their jerseys to the rafters someday, too. Right now, Leonard is a seeming lock for the honor with the Raptors, where his brief-but-fruitful stay there gave their rabid fan base their first NBA championship.

Dwight Howard (Magic): After his first eight seasons in Orlando, Howard had a near slam-dunk case for the Hall of Fame and retired jersey status. Yes, his exit from Orlando was messy. And he has yet to find a way to part ways with any of the other franchises on good terms. Still, you cant overlook his Magic-era feats: All-Star berths, three Kia Defensive Player of the Year awards, five All-NBA first team nods and a Finals trip in 2009.

Sekou Smith is a veteran NBA reporter and NBA TV analyst. You can e-mail himhere, find his archivehereand follow himon Twitter.

The views on this page do not necessarily reflect the views of the NBA, its clubs or Turner Broadcasting.

View original post here:
21 active stars who should have their jersey retired someday - ABS-CBN Sports

Here are Bank of America’s top 10 investing themes to watch over the next decade – CNBC

With the decade drawing to a close, Bank of America has identified 10 important investing themes to watch over the next 10 years. Underpinning the list is the tectonic societal shifts that the firm anticipates will play out over the next decade.

The firm said the coming decade will be "unlike any before it" as the world's social, environmental, political and economic systems face "escalating challenges." Megatrends will reach their boiling point in the 2020s, which will lead to changes in how governments, companies, markets and society more broadly operate, BofA predicts.

"We expect the 2020s will overhaul old paradigms, disrupt business models, and produce new trends that will shape our future. In the next 10 years, we should see increased automation, a global recession, unprecedented innovation, serious environmental challenges, the death of quantitative easing, tectonic shifts in demographics and the end of globalization," Bank of America analysts led by Haim Israel said in a note to clients Monday.

CNBC was granted permission to publish the full list.

Source: Bank of America

Bank of America says globalization has already peaked, which means that over the next decade there will be a greater focus on all things local.

"The 1981-2016 era of unchecked flow of goods, people and capital is coming to an end, catalyzed by the widespread recognition that while globalization has meant lower consumer prices, it has also meant slower growth, precarious employment and social disruption," Israel wrote.

The firm anticipates that while at first disruption in the global flow of things will increase the cost of doing business, eventually it will lead to a rebalancing that will raise productivity and set the global economy on a path to higher, sustainable growth.

"Countries will develop explicit national industrial policies and boost spending on R&D to foster local innovation, protect nascent industries, and shield national champions from hostile foreign takeovers," the analysts said.

Within a more nationalistic backdrop, investors should opt to own real assets like commodities, real estate and precious metals, as well as infrastructure and defense names. As things shift closer to home, small-cap and value stocks look better positioned than large-cap and growth stocks, according to the report.

The firm predicts that a number of other things will peak during the 2020s, including oil, cars and inequality; the population will age and people will own fewer things as the economy shifts from ownership to the sharing.

The economic picture entering the next decade isn't exactly rosy. Stocks may be hovering around all-time highs, but a record 90% of recipients in the BofA Global Fund Manager Survey said the world's economy is late in the boom cycle.

"We leave the 2010s stuck in an economic regime characterized by low growth and low inflation. Real GDP has averaged just 2% in the US, 1% in the EU and Japan, and halved from 12% to 6% in China as it rebalances towards a consumer rather than export-led economy," the firm said.

Bank of America sees today's bond market bubble as the "biggest vulnerability" for markets heading into 2020.

"In the coming years a policy mistake [inflation targeting/modern monetary theory] and/or the start of policy impotence (central banks pushing on a string) will likely cause a jump in interest rate volatility, end the decade-long bullish combo of minimum rates-maximum profits, and signal the big top in asset prices. A disorderly rise in bond yields would likely cause extreme pain as Wall St deleverages," the note said.

To hedge against a coming recession, the firm said to own things like gold and gold miners, as well as companies in monopoly areas like the utility sector since companies having pricing power even in downturns.

High-quality companies in areas where there's low political risk, and only a few key players, should also do well. Bank of America included things like national defense, waste management, data processing and payments, and global beverages in this category.

An aging worldwide population coupled with the rise of a middle class in emerging markets will shift consumer habits and tastes over the next 10 years.

"Companies will need to adapt or face disruption from the emerging spending power not just of Millennials but also of new Gen Z consumers (e-commerce, same-day delivery)," the firm said. Tech-compatability, sustainability, and experiences over traditional "goods" are among the trends expected to accelerate over the next decade

As people age, there will also be a big opportunity for advancements in healthcare targeting lift expectancy and quality. "Immortality' may prove the most interesting secular theme in the 2020s," Israel said.

Consumers are increasingly focused on the many and broad implications of climate change, which creates opportunity in areas like clean energy, electric vehicles, energy efficiency, new farming, water infrastructure and meat alternatives.

"Efforts to curb global warming require behavioral and systemic changes that will provide substantial opportunities for investors. ... BofAML estimates that the clean energy market is already worth [$300 billion], while the global waste industry presents a [$2 trillion] opportunity. Likewise, water infrastructure will need a minimum cumulative investment of [$7.5 trillion to 2030] to keep up with projected growth," the firm said.

A sharper focus on climate change will also be one of the forces driving an increase in environmental, social and corporate governance and impact investing over the next decade.

"We enter the 2020s with capitalism focused purely on profit maximization on the cusp of reform as it shifts away from shareholder supremacy towards greater involvement of stakeholders, i.e., moral capitalism," the firm said.

Bank of America estimates that $20 trillion the size of the S&P 500 will flow into environmental, social and governance strategies over the next 20 years as millennials and Generation Z become the primary investors.

The U.S. and China are currently battling to lead global artificial intelligence innovation, but this "splinternet" divide will disappear by 2030 as China becomes the world leader, Bank of America said.

"We believe the current trade war will transition towards a tech war in the 2020s, which will see a new 'arms race' between the US and China to reach national superiority in technology over the long term vis-a-vis Quantum Computing, Big Data, 5G, Artificial Intelligence, Electric Vehicles, Robotics, and Cybersecurity etc.," the firm said.

Baidu, Alibaba and Tencent will be primed to take advantage of the AI revolution, at the expense of the so-called "FAANG" stocks Facebok, Amazon, Apple, Netflix and Google-parent Alphabet.

"Just over half the population is connected in China but that is already nearly triple the number of internet users in the US, suggesting China's annual mobile data traffic could grow 56% compared with 35% in the US. ... With favorable policies and government backing, China's technology companies are likely to be better placed to take advantage of these data trends," the firm said. Robotics and automation are another key theme to watch over the next decade as developments could jeopardize up to 50% of worldwide jobs by 2035.

As everything shifts online and becomes data-fied, this "ubiquitous connectivity" will alter society's fabric, particularly in cities. Bank of America called the smart city theme "one of the biggest investible universes" as technology and data transform everything from urban transportation to city security to temperature control in office buildings.

"Sensor and [internet of things] deployment is mostly in cities, opening major opportunities for semiconductor, sensor and software suppliers. For example, the expansion of the London Ultra Low Emission Zone for polluting vehicles will require cameras/sensors and software services," the firm cited as one industry set to benefit from smart cities.

Bank of America predicts that the space industry could be worth $1 trillion by 2030, with aerospace and defense companies set to reap the rewards.

"New technology (reusable rockets), innovative speedy private companies, miniaturisation of electronics and new services (internet from space, space tourism) could revolutionize space like never before," the firm said.

Declining costs and greater functionality will lead to an increased interest in space from individuals, countries and companies. "The next decade is set to be the most exciting ever for space," Bank of America said.

CNBC's Michael Bloom contributed reporting.

Read more from the original source:
Here are Bank of America's top 10 investing themes to watch over the next decade - CNBC

Dwyane Wades all-time starting 5 features players he won titles with – ClutchPoints

Former Miami Heat (and Chicago Bulls and Cleveland Cavaliers) star Dwyane Wade made it known who his starting five would be if he could draw up one squad from his tenure in the league.

During an interview with Complexs Alex Wong, Wade lays out who his five would be, starting with himself being the point man of the group.

Its gotta be the guys I won championships with, Wade said. Ray Allen at the two, LeBron at the three, Bosh at the four and Shaq at center. And wed have Udonis Haslem as the sixth man.

That would be a formidable squad to say the least. Alongside James and Bosh, Wade collected two NBA championships, while his first was won with Shaquille ONeal anchoring the squad in the post.

Allen, of course, hit one of the most pivotal threes in league history during the 2013 NBA Finals, forcing a Game 7 against the San Antonio Spurs, which led to the Heat claiming their second consecutive ring.

Maybe the most interesting inclusion is that Wade sees himself running the point with James working off the ball. It comes as no surprise that Wade would stack his top five with players that helped lead him to basketball immortality, even as he could make a strong case for having suited up with the strongest collection of teammates in league history.

While James is the only active member still getting up shots in the league, never say never for this quintet, who could still likely get theirs on any given day.

Excerpt from:
Dwyane Wades all-time starting 5 features players he won titles with - ClutchPoints

Is The Flash new tonight on The CW? Upcoming season 6… – CarterMatt

IsThe Flashnew tonight on The CW? Within this article, were going to offer news on that but then also the stories coming up.

Lets go ahead and get some of the bad news out of the way there is no new episode of the superhero show on the air tonight instead, youre going to be waiting for a week to see the further adventures of Barry Allen and company. This is the first time this season that there isnota new episode on the air, so consider this a chance to catch your breath. After all, there is somecrazystuff ahead! Were building towardsCrisis on Infinite Earthssure, but there is also going to be a showdown coming between Barry Allen and Bloodwork. He is the Big Bad for the first half of the season, and he also may teach the title character a thing or two about immortality every single step of the way.

Without further ado, lets go ahead and share a handful of additional details now all about whats coming.

Episode 6, License to Elongate RALPH GOES DEEP UNDERCOVER Barry (Grant Gustin) turns his attention to prepping Elongated Man (Hartley Sawyer) for life after Crisis and without The Flash, but Ralph ultimately teaches Barry a lesson. Meanwhile, Cecile (Danielle Nicolet) faces her own moment of self-discovery while helping a recuperated Chester P. Runk (guest star Brandon McKnight) reclaim his identity. Danielle Panabaker directed the episode written by Thomas Pound & Jeff Hersh (#606). Original airdate 11/19/2019.

Episode 7, The Last Temptation of Barry Allen: Part 1 PART ONE OF THE MID-SEASON FINALE As Barry Allen (Grant Gustin) stands on the threshold of his impending death in Crisis, his convictions are tested when the monstrous Dr. Ramsey Rosso (guest star Sendhil Ramamurthy) infects The Flash with a mysterious, hallucinogenic contagion. Meanwhile, reporter Iris West-Allen (Candice Patton) uncovers a vast conspiracy. Chad Lowe directed the episode written by Jonathan Butler & Gabriel Garza (#607). Original airdate 11/26/2019.

The second part of the midseason finale will air on December 3, and thenThe Flashis going from there directly into the crossover. In other words, there is alotof exceptional stuff coming where lives are in danger and the stakes of the entire multiverse are there.

Related News Be sure to get some more information right now regarding The Flash!

Are you bummed that the show isnt on the air tonight? Be sure to share right now in the comments, and remember to stick around to get some more information when it comes to the series. (Photo: The CW.)

Original post:
Is The Flash new tonight on The CW? Upcoming season 6... - CarterMatt

Staging the Self in Country Music – Splice Today

One of the ways for singers to make a bid for country immortality is to create themselves as characters or legendsa Hank Williams, a Patsy Cline. Hank still provides the template for traditionalist-minded male artists such as Cody Jinks; it's impossible to think of the character Jinks inhabits on his recent albums except in relation to the line-up of self-destructive hyper-emotional geniuses like Johnny Cash, George Jones, even Chris Stapleton. On the other side of the great gender dividethough Tammy, Loretta, and Reba provide templatesthe materials out of which female artists like Miranda Lambert are assembling the characters they inhabit are by and large of more recent vintage. Really, Miranda's invented a lot of them herself.

Every month many people try to stage themselves as country legends, and fail. The music is what makes it stick, if it does, and Cody and Miranda definitely have that part. Jinks and Lambert are both Texans, which is a good start, and make a good match on a playlist. Their bliss may be doomed, however, due to their extremely dark sides. Are they partying happily or devoured by the darkness within? Always hard to tell one from the other.

Country is musical tradition, but it's centrally also atheatricaltradition, with the characters presented on stage complexly related to the humans singing the song. As in hip-hop, for example, it's hard to separate the memoir from the novel, the art from the artist, the story from the truth. Both singers portray themselves as victims of themselves, helpless to resist when their dark and/or party side emerges. They're sorry if they hurt you, but they're not really in control. Miranda takes this in fairly good humor; Jinks uses it as an occasion for self-examination and self-laceration. Or at least, the character that narrates his songs does that.

A couple of weeks ago, Jinks, a recovering heavy metal singer whos as good as anyone working in a traditional country vein right now, released two albums, more or less simultaneously. Perhaps these are meant as a kind of yin-yang:After the Firethe light side,The Wantingthe dark. That seems to be the governing metaphor of the project, as summarized on the latter album's art, featuring a black and a white wolf in some sort of profound or goofy merger.

I've been the song carried in on the breeze. I've wept with willows and I've fell with leaves. Well, I am the badlands and the silence it holds. A warrior who walks but is never alone. There's a black and a white wolf in me. And I live and I die by which one I feed. It's a war old as time, this fighting inside. And I live and I die by which one I feed.

You'd have to say that's dramatic. Perhaps overly so, and the Jungian symbolism of masculinity threatens to tip over into self-parody: "It's the people who love me who suffer the most," he says, in a line that could summarize Waylon's later output, and a lot of other people's too. One is not entirely surprised when he sings, "I'm just a guy with a wounded mind." It's as though the wild hijinks (pun) and legendary self-destruction of aWaylon Jenningsor David Allan Coe has been transferred by Jinks to "the inner terrain," rendered over into a pure psychodrama. But as I listened and began muttering at my speaker that Cody ought to lighten up, he beat me to it: "Maybe the light at the end of the tunnel ain't a train," he admits. That would be a dangerously positive outcome for this sort of country singer, but then again there is that Maybe.

If anyone can be convincing on something like this, it's Jinks and his band and production team. Country hasn't sounded any better since early Alan Jackson, or Pete Anderson'srecordingswith Dwight Yoakam. "Think Like You Think, for example, is given a perfect arrangement, as traditional as could be imagined, and there are references everywhere to classic country, particularly the neo-traditionalist phase (say, 1989-95): John Anderson ("The Wanting" echoes "Seminole Wind") orRicky Van Shelton, but also John Prine, to whom everyone is paying homage these days. The fiddle kills. The drums swing beautifully and are mixed with great presence. There's even a Bob Willsy instrumental workout ("Tone Deaf Boogie"). The basic Waylon thump of "The Raven and the Dove" (again with the light and dark sides of Jinks) sounds newly alive. Jinks delivers the material with the sort of authority that lends it credibility; he rolls along pretty deep.

Miranda'sWildcardpicks up her persona where she left off before she paused time itself for hermasterpiecedouble setThe Weight of These Wings(2016). Here she's back to the rowdy girl who means to do well but doesn't always, or always doesn't. Meanwhile all the material performed by the Queen of Country Music takes place against her rocky, very interesting love life. "I've got a track record; my past is checkered," she tells us, perhaps unnecessarily. "Girls like me don't mean it but we don't know better." She's not with Blake Shelton, of course, or Anderson East, but has married a policeman from Staten Island and moved to NYC. There are occasional signs of this, not only in the lyrics but also in a couple of flirtations with Taylor Swifty pop (on "Mess With My Head," which I'm not quite feeling, and "Settling Down," which I am).

She has more than earned the right to embody an archetype, and it's the music rather than the actual love life that constructs Miranda as a character and a legend, in a long series of four-minute vignettes through which she drinks, loves, swaggers, loses, and swears sweetrevenge, her specialty. "It'll all come out in the wash," she promises. "You take the sin and the men and you throw them all in, and you put that sucker on spin." These days, though, she's winking at her former threats of violence against assholes she has dated, as on "Way Too Pretty for Prison," a tribute to or swipe from Brandy Clark'sStripes. But perhaps she was always winking.

Whatever the reality of Miranda Lambert's life may be, she portrays herself, in her own words, as a white trash bitch. Wait, don't blameme for my vulgar diction,blame such lyrical constructions as "I just can't keep my white trash off the lawn" and her new candidate for Miranda national anthem, "Pretty Bitchin'." On the other hand, it's often the gentler, more rueful or meditative songs that sneak up on you and remind you that Lambert can really sing. She, too, proves that classic traditional country is still possible, on "(He Can't Love Me Like)Tequila Does." It's hard, as often with a country star you like, not to worry a little about the alcohol. On the other hand, correlating "Miranda Lambert" with Miranda Lambert is never a straightforward matter.

On this album, she's almost willfully true to the larger-than-life character she inhabited in her classic series of albums from the early 2010s. "I'm like a locomotive; I don't run out of steam. New York seems okay. I'm a little more Tennessee, and I've got whiskey in my veins." But like Jinks with his light at the end of the tunnel, Lambert goes for small redemptions, as on "Bluebird." I'm wondering, as she seems to be, how well NYC is going to work for her in the long run. She co-wrote all the tracks here, keeping autobiography in play, but she wrote with everyone: Luke Dick, Natalie Hemby and Lori McKenna (recently spotted among theHighwomen), Ashley Monroe, Brent Cobb, Jack Ingram, etc. And she's a model foremergingfemale country singers; maybe she'll be their Hank.

If I were pondering what the future holds for Cody and Miranda, Id speculate that in their casesas perhaps in our ownwell witness a serial depersonification, or a removal of masks. Or perhaps just a mutation; eventually, if Jinks survives all those dark corners of his own mind and Miranda all those "dark bars" where she still apparently hangs out, they'll be meditating ruefully on theirmisspent youth, or at least the misspent youth of the characters they've created.

Follow Crispin Sartwell on Twitter: @CrispinSartwell

Visit link:
Staging the Self in Country Music - Splice Today

‘Doctor Sleep’ tries, but ultimately fails to live up to its unforgettable source material – Bangor Daily News

Doctor Sleep, the latest cinematic adaptation of a Stephen King novel to hit the big screen, has everything going for it to be a really good movie. Excellent actors, such as Ewan McGregor and Rebecca Ferguson. Artful, restrained cinematography. Thrilling source material.

Unfortunately, Doctor Sleep a sequel to The Shining, both on the page and on screen just cant live up to either Kings novel or to the iconic 1980 Stanley Kubrick film that came before it. Its not a bad movie. Its just not a good movie. Its an OK movie.

The plot revolves around a grownup Dan Torrance (McGregor), the child protagonist of The Shining. A recovering alcoholic, he has run away from his childhood trauma and now lives in rural New Hampshire, where he uses his psychic powers (his shine) to help hospice patients pass away comfortably. Hes living relatively peacefully until he encounters Abra Stone, a teenager who has the same sort of psychic powers that he does except even more powerful.

Abra, it turns out, is being chased by a dangerous cult called the True Knot, who search out people with those psychic powers, torture them and then literally feed off their power before killing them. This gives the cult members immortality, essentially, as well as some other limited powers of their own.

The True Knot is led by Rose the Hat, played with malevolent relish by Rebecca Ferguson. Ferguson is by far the best part of Doctor Sleep her villain is sexy, sensual and decidedly evil, and its a delight to hate her as she does her wicked deeds.

McGregor plays Dan Torrance in a fairly subdued way which may make sense, given the amount of trauma the character has undergone in his life, but makes him far less interesting than Rose, or than his teenage companion Abra, played by the young actor Kyliegh Curran, who imbues her with youthful energy.

As with so many Hollywood movies these days, Doctor Sleep is simply too long, clocking in at more than two and a half hours that tend to drag, in between flashes of excitement. In that way, it might have been better served as a limited TV series, rather than a feature film.

It also is haunted by a very real ghost: the ghost of Kubricks The Shining, a truly iconic piece of filmmaking that, all perfectly reasonable criticisms of Kubricks work aside, it is near-impossible for director Mike Flanagan to live up to. Flanagan is clearly a skilled filmmaker, but trying to follow something like The Shining is really a thankless job.

It is reminiscent of another recent movie that suffered from the weight of an unforgettable original film: Blade Runner 2049, a film that, try as it might, was just never going to be as good as the original Blade Runner. Despite having all the cinematic pieces in place acting, art direction, script, source material it just leaves you wanting to watch the first one instead.

See the original post:
'Doctor Sleep' tries, but ultimately fails to live up to its unforgettable source material - Bangor Daily News